Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely the case for Viela Bio.
Viela will emerge with six drug candidates, including one drug in Phase 2 development, and $250 million in funds.
The candidates will be carried over from MedImmune’s portfolio and mainly focus on inflammation and autoimmunity, allowing AstraZeneca to once again re-focus its efforts into its key therapeutic areas.
